All News
Debate over Alcohol and Methotrexate Precautions
Drs. Kremer and Weinblatt have responded to a recent Annals of Rheumatic Disease article regarding the hepatic risks of alcohol use with methotrexate (MTX) therapy authored by Humphries et al. (Citation source: http://buff.ly/2r70uuz)
Read Article
2017 ACR Guideline on Glucocorticoid-Induced Osteoporosis
The American College of Rheumatology has updated its 2010 guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. The guideline provides recommendations on assessing fracture risk and treatment for adults and special patient populations, including women of childbearing potential, adults treated with very high-dose glucocorticoids, adults with organ transplants, and children ages 4-17.
Read Article
Upadacitinib Effective in Rheumatoid Arthritis
AbbVie released the preliminary results of a rheumatoid arthritis trial wherein its Jak inhibitor, upadacitinib, was tested against placebo, and shown to be superior in established RA patients who have failed prior DMARD therapy.
Read Article
Nurse-Led Patient Care in Rheumatology
Manpower in rheumatology is about to be a major problem for the next several decades: not enough trainees, a "tsunami of retiring older white rheumatologists", and an aging baby-boomer, arthritis-primed population will strain current resources and manpower. Moreover, necessary services will not likely be available to those in need and there may be a significant maldistribution of adequate rheumatologic care.
Read Article
Biosimilar Reports – May 2017
Biosimilars continue to command a great deal of research, development and attention given the promise of significant cost savings and potentially wider use for those in need. Biosimilar Reports is an ongoing series dedicated to advances, discussions and developments in biosimilar agents intended for use by rheumatologists.
Read Article
Higher Fracture Risks with Prolonged Bisphosphonate Use in Older Women
The Journal of the American Geriatric Society has reported that older women receiving bisphosphonate therapy for greater than 10-13 years were more likely to suffer from fractures.
Read Article
Both Undertreatment and Overtreatment Common in JIA
Kimme L. Hyrich, MD, PhD, of the University of Manchester in the United Kingdom, and colleagues point out that because of the lack of consensus in diagnostic criteria, "the same child could be classified as 'in clinically inactive disease' or having active disease at the same time point between clinicians or hospitals."
Read Article
Golimumab Fails in Polyarticular Juvenile Arthritis
Treatment options for children with active polyarticular juvenile idiopathic arthritis (polyJIA) have lagged behind that seen with adult rheumatoid arthritis.
Read Article
Biologics Before Triple DMARD is Not Cost Effective in Rheumatoid Arthritis
Stepping up to biologic therapy when methotrexate (MTX) monotherapy fails was not shown to be cost effective, compared to first trying triple therapy, in a rheumatoid arthritis (RA) study published in Annals of Internal Medicine.
Read Article
High Fiber Intake May Decrease Osteoarthritis Knee Pain
Dai, Felson and colleagues report in Annals of Rheumatic Disease that high dietary fiber lowers the risk of symptomatic osteoathritis (SxOA), but the radiographic benefits remain unclear. (Citation source http://buff.ly/2rHv9yd)
Read Article
The RheumNow Week in Review - 26 May 2017
Dr. Jack Cush Reviews highlights from the past week on RheumNow.com:
Read Article
IL-6 Inhibitor Kevzara Granted FDA Approval for Rheumatoid Arthritis
The FDA has approved sarilumab (Kevzara), a new IL-6 inhibitor co-developed by Regeneron and Sanofi's, for use in adults with moderate to severe rheumatoid arthritis (RA).
Read Article
Anti-Sclerostin Drug Hampered by Heart Problems
Reuters reports that FDA approval of romosozumab (brand name Evenity) may be held up because of higher rates of cardiac events seen in a late-stage clinical trial.
Read Article
The RheumNow Week in Review – 17 May 2017
Dr. Jack Cush reviews highlights and updates from the past week on RheumNow.com:
Read Article
Inflammatory Arthritis Stable after Switch to Biosimilar Infliximab
The DANBIO registrys has demonstrated that switching from infliximab (Remicade) to biosimilar CT-P13 (Inflectra in the U.S., Remsima in Europe) does not appear to have any negative effect on inflammatory arthritis disease activity, Danish researchers reported.
Read Article
Educational Intervention Facilitates Treat-to-Target Management in Rheumatoid Arthritis
Treat-to-target education through group-based quality improvement sessions can result in wider use of treat-to-target in practice, according to researchers.
Read Article
NOR-SWITCH Study Validates Biosimilar Use in Multiple Indications
Lancet reports the results of the NOR-SWITCH study - a trial performed in Norway as biosimilars were being introduced.
Read Article
Rituximab May Benefit Rheumatoid Lung
A retrospective study shows that rituximab treatment of RA-related interstitial lung disease may improve or forestall ILD progression.
Read Article
The RheumNow Week in Review – 12 May 2017
Dr. Jack Cush highlights the big stories, news and articles from this week at RheumNow.com.
Read Article
ACP Guideline Recommends Generic Bisphosphonates But Limits DEXA Use
The American College of Physicians (ACP) has updated its 2008 clincial practice guideline on the treatment of low bone density and osteoporosis to prevent fractures in men and women. The new guideline is in favor of generic bisphosphonate use and recommends against using menopausal estrogen therapy and against DEXA monitoring during the first 5 years.
Read Article
